CN108065400A - One kind can antianaphylactic probiotic powder - Google Patents
One kind can antianaphylactic probiotic powder Download PDFInfo
- Publication number
- CN108065400A CN108065400A CN201611005216.2A CN201611005216A CN108065400A CN 108065400 A CN108065400 A CN 108065400A CN 201611005216 A CN201611005216 A CN 201611005216A CN 108065400 A CN108065400 A CN 108065400A
- Authority
- CN
- China
- Prior art keywords
- parts
- antianaphylactic
- lactobacillus
- probiotic powder
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000843 powder Substances 0.000 title claims abstract description 39
- 230000002804 anti-anaphylactic effect Effects 0.000 title claims abstract description 37
- 239000006041 probiotic Substances 0.000 title claims abstract description 36
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 36
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 36
- 241000894006 Bacteria Species 0.000 claims abstract description 23
- 239000003085 diluting agent Substances 0.000 claims abstract description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 13
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 11
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 10
- 241000186605 Lactobacillus paracasei Species 0.000 claims abstract description 9
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract description 8
- 229940001882 lactobacillus reuteri Drugs 0.000 claims abstract description 8
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 7
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 7
- 239000000470 constituent Substances 0.000 claims abstract description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 5
- 235000013373 food additive Nutrition 0.000 claims description 15
- 239000002778 food additive Substances 0.000 claims description 15
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 claims description 12
- 239000003205 fragrance Substances 0.000 claims description 11
- 235000013351 cheese Nutrition 0.000 claims description 7
- LDWSIWPELARINM-UHFFFAOYSA-N 10,12-dimethylhenicosan-11-one Chemical class CCCCCCCCCC(C)C(=O)C(C)CCCCCCCCC LDWSIWPELARINM-UHFFFAOYSA-N 0.000 claims description 6
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 claims description 6
- 239000005770 Eugenol Substances 0.000 claims description 6
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 claims description 6
- 235000016213 coffee Nutrition 0.000 claims description 6
- 235000013353 coffee beverage Nutrition 0.000 claims description 6
- 229960002217 eugenol Drugs 0.000 claims description 6
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 3
- 235000013406 prebiotics Nutrition 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 abstract description 10
- 208000010668 atopic eczema Diseases 0.000 abstract description 10
- 241001608472 Bifidobacterium longum Species 0.000 abstract description 8
- 229940009291 bifidobacterium longum Drugs 0.000 abstract description 8
- 210000000987 immune system Anatomy 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- 235000013305 food Nutrition 0.000 abstract description 7
- 235000021255 galacto-oligosaccharides Nutrition 0.000 abstract description 6
- 150000003271 galactooligosaccharides Chemical class 0.000 abstract description 6
- 230000036541 health Effects 0.000 abstract description 4
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 abstract description 3
- 229920002498 Beta-glucan Polymers 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 235000021472 generally recognized as safe Nutrition 0.000 abstract description 2
- 230000007365 immunoregulation Effects 0.000 abstract description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 26
- 239000003814 drug Substances 0.000 description 21
- 235000014655 lactic acid Nutrition 0.000 description 13
- 239000004310 lactic acid Substances 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 11
- 235000013618 yogurt Nutrition 0.000 description 10
- 229940079593 drug Drugs 0.000 description 8
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- 208000026935 allergic disease Diseases 0.000 description 5
- 230000007815 allergy Effects 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 210000001539 phagocyte Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- 102000009016 Cholera Toxin Human genes 0.000 description 2
- 108010049048 Cholera Toxin Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229940088529 claritin Drugs 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010029379 Neutrophilia Diseases 0.000 description 1
- 235000011203 Origanum Nutrition 0.000 description 1
- 240000000783 Origanum majorana Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241000031670 Saccharopolyspora thermophila Species 0.000 description 1
- 241001591005 Siga Species 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/165—Paracasei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses one kind of food or technical field of health care food can antianaphylactic probiotic powder, this can the constituent of antianaphylactic probiotic powder be：300 1000 parts of galactooligosaccharide,300 800 parts of oligoisomaltose,400 900 parts of yeast beta glucan,100 300 parts of Lactobacillus paracasei,100 300 parts of Lactobacillus rhamnosus,100 300 parts of lactobacillus reuteri,100 300 parts of lactobacillus acidophilus,100 300 parts of bifidobacterium longum and excipient and diluent,The present invention regulates and controls therapy using allergic immune,It is the immune system using natural immunoregulation usually body,It is suitble to any age level,It is more suitable for the parent use that is pregnant,The occurrence probability of newborn's allergic constitution can be resisted,Wherein use Lactobacillus paracasei,Lactobacillus rhamnosus,Lactobacillus reuteri,Lactobacillus acidophilus and bifidobacterium longum,The superpower zoarium of five bacterium,It is effectively improved allergic constitution,Using the bacterium colony of generally recognized as safe,It is without any side effects.
Description
Technical field
The present invention relates to food or technical field of health care food, and being specially one kind can antianaphylactic probiotic powder.
Background technology
Allergy is exactly that exotic, such as bacterium, virus, pollen, dust substance are generated immune work for harmful object
With the mast cell in immunocyte is made to start to activate, disengages histamine, histamine can cause Marjoram Extract, vascular permeability
The a series of effects such as property increases, itches, smooth muscle contraction and reflection, small, there is erythema measles in skin, heavy then cause skin
The inflammation such as swelling, fever show, self immune system is exactly a big number storehouse, it is known which substance be it is beneficial to body,
Which substance is insalubrious, is then marked, and is launched a offensive to harmful substance, to benefit materials, is absorbed.And
Allergy is the hyperfunction performance of self immune system, no matter whether the substance come in is beneficial to body, all labeled as being harmful to, so
After attacked, Anaphylactic mediator will be caused to reach a certain concentration, then acted on mucous membrane, so as to cause allergic reaction,
The characteristics of reaction, is rapid breaking-out, strong reaction, disappears comparatively fast；Histocyte will not be generally destroyed, tissue will not be caused to damage
Wound, there is apparent genetic predisposition and individual difference, and existing Claritin using effect is undesirable, for this purpose, we have proposed
One kind can antianaphylactic probiotic powder.
The content of the invention
It is an object of the invention to provide one kind can antianaphylactic probiotic powder, it is mentioned above in the background art to solve
The problem of existing Claritin using effect is undesirable.
To achieve the above object, the present invention provides following technical solution：One kind can antianaphylactic probiotic powder, this can anti-mistake
The constituent of quick probiotic powder is：300-1000 parts of galactooligosaccharide, 300-800 parts of oligoisomaltose, yeast β-Portugal
400-900 parts of glycan, 100-300 parts of Lactobacillus paracasei, 100-300 parts of Lactobacillus rhamnosus, lactobacillus reuteri 100-300
Part, 100-300 parts of lactobacillus acidophilus, 100-300 parts of bifidobacterium longum and excipient and diluent.
Preferably, it is described can antianaphylactic probiotic powder include one or more than one kinds of more than strain.
Preferably, the excipient and diluent are physiologically acceptable food additives.
Preferably, the food additives are yogurt, cheese or coffee.
Preferably, the viable count that can be in antianaphylactic probiotic powder is higher than 3.0 × 106CFU/ grams.
Preferably, added with fragrance in the food additives, and the fragrance includes eugenol and 2- undecyl ketones.
Compared with prior art, the beneficial effects of the invention are as follows：The present invention regulates and controls therapy using allergic immune, is profit
With the immune system of natural immunoregulation usually body, make it have the ability of " reinforcing righting " and reach " autonomous strong
The effect of health is a kind of nature and the humanizing therapy being free from side effects.It is suitble to any age level, is more suitable for the parent use that is pregnant,
The occurrence probability of newborn's allergic constitution can be resisted, wherein using Lactobacillus paracasei, Lactobacillus rhamnosus, Luo Yishi breast bars
Bacterium, lactobacillus acidophilus and bifidobacterium longum, the superpower zoarium of five bacterium, are effectively improved allergic constitution, using the bacterium colony of generally recognized as safe, nothing
Any side effect.Target user：The all groups such as child, pregnant woman, old man, youth.It is applicable in symptom：Allergic rhinitis, anaphylaxis
Conjunctivitis, Atopic dermatitis, nettle rash, allergic asthma, enteritis anaphylactica, hypoimmunity additionally can be used for improving
Pregnant woman's allergic constitution, eugenic health.
Description of the drawings
Fig. 1 is not injected into medicine group standards of grading figure for invention；
Fig. 2 is invention primary drug group standards of grading figure；
Fig. 3 is invention secondary agents group standards of grading figure；
Fig. 4 is invention three-level medicine group standards of grading figure.
Specific embodiment
Below in conjunction with the attached drawing in the embodiment of the present invention, the technical solution in the embodiment of the present invention is carried out clear, complete
Site preparation describes, it is clear that described embodiment is only part of the embodiment of the present invention, instead of all the embodiments.It is based on
Embodiment in the present invention, those of ordinary skill in the art are obtained every other without making creative work
Embodiment belongs to the scope of protection of the invention.
Human allergy's basic reason is immune system, and the immune system of human body can be divided into two large divisions：Congenital immunity energy
Power and compliance immunocompetence, lactic acid bacteria are not yet clear and definite so far to the regulation mechanism of immune system, caused by different lactic acid bacterias
Immune response it is also different, conclusion is carried out to the relation of lactic acid bacteria and immune response by testing.
Influence of the lactic acid bacteria to the phagocytic activity of phagocyte：
The phagocytic activity of phagocyte can be as the index of nonspecific immune reaction.
Phagocyte in blood includes macrophage, neutrophilia multinuclear ball etc., when in pathogen intrusive body, can it is non-specially
The carry out phagocytosis of one property.
Using animal as many of pattern the study found that giving the various lactic acid bacterias of mouse feeding or the breast system containing lactic acid bacteria
Product, after 10 or 28 days, compared with the control group mouse of no feeding lactic acid bacteria, hence it is evident that increase periphery blood white blood cell and abdomen
The phagocytic activity of film macrophage.
Lymphocyte function can be as the index of specific immune response.
It can be activated after lymphocyte and metastatic antigen binding, activation latter medicine characteristic is exactly breeder reaction, lymph
The breeder reaction of cell can be used to detect the quality of lymphocyte function.
Relevant research is mostly animality experiment.To small white mouse difference feeding lactic acid bacteria L.rhamnosus,
L.acidophilus or B.lactis 10 compares after 28 days with the control group of no feeding lactic acid bacteria, hence it is evident that promotes spleen
Breeder reaction of the dirty cell to T lymphocytes mitogen-ConA and bone-marrow-derived lymphocyte mitogen-LPS.
Relevant research, be mostly animality experiment, to mouse distinguish feeding L.rhamnosus, L.acidophilus or
B.lactis10 days, and the infection for giving oral cholera toxin for 0-7 days, it turns out that the control with no feeding lactic acid bacteria
When group mouse compares, it can significantly increase Serum antibody concentrations, in the research with Tejada-simon (1999), give small
Yogurt in mouse feeding four (including with traditional yogurt of S.thermophilus bearings and containing L.acidophilus and
Traditional yogurt of Bifidobacterium spp.) three weeks, and the infection for giving oral cholera toxin respectively with the 0-14 days,
It turns out that control of the traditional yogurt groups of also L.acidophilus and Bifidobacteriumspp. compared with feeding milk
The concentration of group and tradition yogurt groups, sIgA and serum IgA is significantly higher.
It is can be found that by above document：Lactic acid bacteria can strengthen nospecific immunity, can also be used as specific immunity
The adjuvant of reaction.And observe influence of the lactic acid bacteria to immune system, it is necessary to be globality.After lactic acid bacteria spark phagocyte,
It can strengthen macrophage and antigen is presented to T lymphocytes.After T lymphocytes are activated, cytokines can be secreted, except gram
Outside the activation of the strong huge phagocyte of system, bone-marrow-derived lymphocyte can also be stimulated, promotes the manufacture of antibody, and the generation of antibody, again
It can strengthen identification capability of the macrophage to antigen.
We compare can influence of the antianaphylactic probiotic powder to the children for suffering from allergic symptom.60 children of random sampling,
(severe, fraction get over Gao Yueyan to the children of age weight allergic symptom in 2-14 Sui during allergy severity score standard ＞ 25 is represented
Weight), it is respectively divided into and is not injected into medicine group, primary drug group, secondary agents group and three-level medicine group, every group of 15 people, and everyone
Extent is substantially similar, the group member of primary drug group, secondary agents group and three-level medicine group everyone take can antianaphylactic benefit
Raw bacterium powder, twice daily, during which totally 4 weeks.Judge allergic symptom severity in (after treatment) scoring in the 1st, 2,3,4 week.Experiment
Room result and can the use of antianaphylactic probiotic powder drug be included in observation together.
Primary drug group use can antianaphylactic probiotic powder ingredient：
This can the constituent of antianaphylactic probiotic powder be：300 parts of galactooligosaccharide, 300 parts of oligoisomaltose, ferment
Female 400 parts of beta glucan, 100 parts of Lactobacillus paracasei, 100 parts of Lactobacillus rhamnosus, 100 parts of lactobacillus reuteri, acidophilus breast
100 parts of bacillus, 100 parts of bifidobacterium longum and excipient and diluent, it is described can antianaphylactic probiotic powder include more than bacterium
One or more than one kinds of kind, the excipient is physiologically acceptable food additives with diluent, the food addition
Agent is yogurt, cheese or coffee, and the viable count that can be in antianaphylactic probiotic powder is higher than 3.0 × 106CFU/ grams,
Added with fragrance in the food additives, and the fragrance includes eugenol and 2- undecyl ketones.
Secondary agents group use can antianaphylactic probiotic powder ingredient：This can antianaphylactic probiotic powder composition into
It is divided into：650 parts of galactooligosaccharide, 550 parts of oligoisomaltose, 650 parts of yeast beta-dextran, 200 parts of Lactobacillus paracasei, mouse
200 parts of Lee's sugar lactobacillus, 200 parts of lactobacillus reuteri, 200 parts of lactobacillus acidophilus, 200 parts of bifidobacterium longum and excipient with
Diluent, it is described can antianaphylactic probiotic powder include one or more than one kinds of more than strain, the excipient and diluent
For physiologically acceptable food additives, the food additives are yogurt, cheese or coffee, it is described can antiallergy
Probiotic powder in viable count be higher than 3.0 × 106CFU/ grams, added with fragrance in the food additives, and the spices bag
Include eugenol and 2- undecyl ketones.
Three-level medicine group use can antianaphylactic probiotic powder ingredient：One kind can antianaphylactic probiotic powder, this can
The constituent of antianaphylactic probiotic powder is：1000 parts of galactooligosaccharide, 800 parts of oligoisomaltose, yeast beta-dextran
900 parts, 300 parts of Lactobacillus paracasei, 300 parts of Lactobacillus rhamnosus, 300 parts of lactobacillus reuteri, 300 parts of lactobacillus acidophilus,
300 parts of bifidobacterium longum and excipient and diluent, it is described can antianaphylactic probiotic powder include more than strain it is a kind of or
More than one, the excipient and diluent are physiologically acceptable food additives, the food additives are yogurt,
Cheese or coffee, the viable count that can be in antianaphylactic probiotic powder are higher than 3.0 × 106CFU/ grams, the food addition
Added with fragrance in agent, and the fragrance includes eugenol and 2- undecyl ketones.
It is essentially identical to be not injected into medicine group, primary drug group, secondary agents group and the symptom of three-level medicine group patient starting,
The later stage treatment as a comparison as a result, by this control variable by way of carry out contrast test, it is as a result more convincing,
Every group of member avoids the situation of special case substantially for 15 people, can be seen that by 4 groups of standards of grading figures and is not injected into medicine group and is used as
Control group, scoring are basically stable at 25 or so, fluctuate less, primary drug group, secondary agents group and three-level medicine group
Patient has apparent scoring downward trend, and comparatively the patient of secondary agents group, which scores, declines comparatively fast.
According to the experimental data for being not injected into medicine group, primary drug group, secondary agents group and three-level medicine group, we can be with
Show that the pharmaceutical formulation optimal proportion treats allergy scheme：
This can the constituent of antianaphylactic probiotic powder be：650 parts of galactooligosaccharide, 550 parts of oligoisomaltose, ferment
Female 650 parts of beta glucan, 200 parts of Lactobacillus paracasei, 200 parts of Lactobacillus rhamnosus, 200 parts of lactobacillus reuteri, acidophilus breast
200 parts of bacillus, 200 parts of bifidobacterium longum and excipient and diluent, it is described can antianaphylactic probiotic powder include more than bacterium
One or more than one kinds of kind, the excipient is physiologically acceptable food additives with diluent, the food addition
Agent is yogurt, cheese or coffee, and the viable count that can be in antianaphylactic probiotic powder is higher than 3.0 × 106CFU/ grams,
Added with fragrance in the food additives, and the fragrance includes eugenol and 2- undecyl ketones.
It although an embodiment of the present invention has been shown and described, for the ordinary skill in the art, can be with
Understanding without departing from the principles and spirit of the present invention can carry out these embodiments a variety of variations, modification, replace
And modification, the scope of the present invention is defined by the appended.
Claims (6)
1. one kind can antianaphylactic probiotic powder, it is characterised in that：This can the constituent of antianaphylactic probiotic powder be：It is oligomeric
300-1000 parts of galactolipin, 300-800 parts of oligoisomaltose, 400-900 parts of yeast beta-dextran, Lactobacillus paracasei 100-
300 parts, 100-300 parts of Lactobacillus rhamnosus, 100-300 parts of lactobacillus reuteri, 100-300 parts of lactobacillus acidophilus, long bifid
100-300 parts of bacillus and excipient and diluent.
2. one kind according to claim 1 can antianaphylactic probiotic powder, it is characterised in that：It is described can be antianaphylactic prebiotic
Bacterium powder is included one or more than one kinds of more than strain.
3. one kind according to claim 1 can antianaphylactic probiotic powder, it is characterised in that：The excipient and diluent
For physiologically acceptable food additives.
4. one kind according to claim 3 can antianaphylactic probiotic powder, it is characterised in that：The food additives are acid
Cheese, cheese or coffee.
5. one kind according to claim 1 can antianaphylactic probiotic powder, it is characterised in that：It is described can be antianaphylactic prebiotic
Viable count in bacterium powder is higher than 3.0 × 106CFU/ grams.
6. one kind according to claim 1 can antianaphylactic probiotic powder, it is characterised in that：Add in the food additives
Added with fragrance, and the fragrance includes eugenol and 2- undecyl ketones.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611005216.2A CN108065400A (en) | 2016-11-11 | 2016-11-11 | One kind can antianaphylactic probiotic powder |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611005216.2A CN108065400A (en) | 2016-11-11 | 2016-11-11 | One kind can antianaphylactic probiotic powder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108065400A true CN108065400A (en) | 2018-05-25 |
Family
ID=62162945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611005216.2A Withdrawn CN108065400A (en) | 2016-11-11 | 2016-11-11 | One kind can antianaphylactic probiotic powder |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108065400A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109007842A (en) * | 2018-10-29 | 2018-12-18 | 广州普维君健药业有限公司 | Have effects that prevent and treat the probiotic composition of allergy and its application |
| CN109645492A (en) * | 2019-01-28 | 2019-04-19 | 新萃斯生物科技(上海)有限公司 | It is a kind of with the child form composite formula and preparation method thereof for controlling allergy in advance |
| CN109645491A (en) * | 2019-01-28 | 2019-04-19 | 新萃斯生物科技(上海)有限公司 | A kind of pregnant woman's compound probiotic formula and preparation method thereof that can control allergy, constipation in advance |
| CN109820044A (en) * | 2018-07-13 | 2019-05-31 | 拜尔普兰（厦门）生物药业有限公司 | A kind of strengthen immunity and assist antianaphylactic probiotics solid beverage formula |
| CN112263597A (en) * | 2020-11-06 | 2021-01-26 | 拉格比(广东)健康科技有限公司 | Probiotic drop for improving allergic constitution |
| CN112273657A (en) * | 2019-07-22 | 2021-01-29 | 安琪酵母股份有限公司 | Probiotic composition for preventing or improving allergic diseases, preparation method and application |
| CN113974168A (en) * | 2021-09-10 | 2022-01-28 | 北京新华联协和药业有限责任公司 | Composite probiotic composition with anti-allergic effect, application and preparation |
| CN114304642A (en) * | 2021-11-25 | 2022-04-12 | 青岛康益生物科技有限公司 | A probiotic product for allergy |
| EP4011383A1 (en) * | 2020-12-11 | 2022-06-15 | Lytone Enterprise, Inc. | Composition for modulating immunity and the use thereof |
-
2016
- 2016-11-11 CN CN201611005216.2A patent/CN108065400A/en not_active Withdrawn
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109820044A (en) * | 2018-07-13 | 2019-05-31 | 拜尔普兰（厦门）生物药业有限公司 | A kind of strengthen immunity and assist antianaphylactic probiotics solid beverage formula |
| CN109007842A (en) * | 2018-10-29 | 2018-12-18 | 广州普维君健药业有限公司 | Have effects that prevent and treat the probiotic composition of allergy and its application |
| CN109645492A (en) * | 2019-01-28 | 2019-04-19 | 新萃斯生物科技(上海)有限公司 | It is a kind of with the child form composite formula and preparation method thereof for controlling allergy in advance |
| CN109645491A (en) * | 2019-01-28 | 2019-04-19 | 新萃斯生物科技(上海)有限公司 | A kind of pregnant woman's compound probiotic formula and preparation method thereof that can control allergy, constipation in advance |
| CN112273657A (en) * | 2019-07-22 | 2021-01-29 | 安琪酵母股份有限公司 | Probiotic composition for preventing or improving allergic diseases, preparation method and application |
| CN112263597A (en) * | 2020-11-06 | 2021-01-26 | 拉格比(广东)健康科技有限公司 | Probiotic drop for improving allergic constitution |
| WO2022095287A1 (en) * | 2020-11-06 | 2022-05-12 | 拉格比(广东)健康科技有限公司 | Probiotic drops for improving allergic constitution |
| EP4011383A1 (en) * | 2020-12-11 | 2022-06-15 | Lytone Enterprise, Inc. | Composition for modulating immunity and the use thereof |
| JP7562502B2 (en) | 2020-12-11 | 2024-10-07 | リトーン・エンタープライズ・インコーポレイテッド | Compositions and uses thereof for modulating immunity |
| CN113974168A (en) * | 2021-09-10 | 2022-01-28 | 北京新华联协和药业有限责任公司 | Composite probiotic composition with anti-allergic effect, application and preparation |
| CN114304642A (en) * | 2021-11-25 | 2022-04-12 | 青岛康益生物科技有限公司 | A probiotic product for allergy |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108065400A (en) | One kind can antianaphylactic probiotic powder | |
| Kalliomäki et al. | Guidance for substantiating the evidence for beneficial effects of probiotics: prevention and management of allergic diseases by probiotics | |
| Michail | The role of probiotics in allergic diseases | |
| JP7497433B2 (en) | Novel use of Lactobacillus paracasei K56 in alleviating intestinal inflammation | |
| Gill et al. | Probiotics and human health: a clinical perspective | |
| US5837238A (en) | Treatment of diarrhea | |
| Liu et al. | The anti‐allergenic properties of milk kefir and soymilk kefir and their beneficial effects on the intestinal microflora | |
| JP4942831B2 (en) | Antiallergic composition | |
| Drago et al. | Changing of fecal flora and clinical effect of L. salivarius LS01 in adults with atopic dermatitis | |
| Lodinová-Žádníková et al. | Prevention of allergy in infants of allergic mothers by probiotic Escherichia coli | |
| Velez et al. | Probiotic fermented milk consumption modulates the allergic process induced by ovoalbumin in mice | |
| CN112869168B (en) | Probiotics prebiotic composition capable of improving gastrointestinal tract immunity and application thereof | |
| WO2007040446A1 (en) | Use of lactobacillus for treatment of autoimmune diseases | |
| CN106413724B (en) | Lactobacillus rhamnosus RHT-3201 conjugated with polysaccharide polymer binder and uses thereof | |
| CN101328468B (en) | Antiallergic lactic acid bacteria | |
| KR20080075971A (en) | Probiotics combined preparations | |
| Xie et al. | Lactobacillus for the treatment and prevention of atopic dermatitis: Clinical and experimental evidence | |
| CN116987608A (en) | Probiotic composition and application thereof in preparation of depression-complicated diarrhea-type irritable bowel syndrome medicines | |
| CN107114794A (en) | Probiotic composition for strengthening antiallergy ability | |
| CN103826648A (en) | Lactobacillus paracasei NCC2461 (ST11) for use by perinatal maternal administration in the reduction and prevention of allergies in progeny | |
| CN109498660A (en) | A kind of application for the lactobacillus plantarum CCFM8610 that can alleviate atopic dermatitis | |
| JP2023037613A (en) | Lactic acid bacterium-containing composition | |
| KR100742900B1 (en) | Lactobacillus rhamnosus idcc 3201 inducing immunoregulatory function and its use | |
| TWI398259B (en) | Composition and use of lactobacillus paracasei strain gmnl-133 in treating atopic dermatitis or other allergic diseases | |
| Hayashi et al. | Anti-atopic dermatitis effects and the mechanism of lactic acid bacteria isolated from Mongolian fermented milk |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20190417 Address after: 410000 Research Building 803, No. 586 Dongfanghongzhong Road, Changsha High-tech Development Zone, Hunan Province Applicant after: Hunan Tiangenle Microecological Health Industry Co., Ltd. Address before: 410000 Room 904, Block B9, Lugu Linyu District, No. 408 Tongzipo West Road, Changsha High-tech Development Zone, Changsha City, Hunan Province Applicant before: HUNAN BOBAI BIOTECHNOLOGY CO., LTD. |
|
| TA01 | Transfer of patent application right | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180525 |
|
| WW01 | Invention patent application withdrawn after publication |